Pharmaceutical News and Articles

New Obamacare Rules Could Raise Deductibles to $31K For Families

FRIDAY, Feb. 27, 2026 The Trump administration is introducing new rules for Obamacare plans that could lower monthly premiums but there s a catch. They raise ho

Placental Vascular Reactivity Can Help ID Fetal Congenital Heart Disease

Placental vascular reactivity (PLVR) can help identify fetal congenital heart disease (CHD), according to a study recently published in Magnetic Resonance in Me

Metabolic Dysfunction Is Main Driver of Chronic Kidney Disease Risk

Metabolic dysfunction, rather than steatotic liver disease (SLD), seems to be the main driver of chronic kidney disease (CKD) risk, according to research publis

Monthly Cabotegravir-Rilpivirine Injections Superior to Standard Oral ART for HIV With Adherence Challenges

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency vir

Muscular Strength Associated With Lower Mortality in Older Women

Greater muscular strength is associated with lower mortality for older women, according to a study published online Feb. 13 in JAMA Network Open.Michael J. LaMo

Stable, Supportive Shoes No Aid for Hip Osteoarthritis

Stable, supportive shoes are not superior to flat, flexible shoes for improving hip osteoarthritis pain while walking, according to a study published online Feb

FDA Approves Desmoda (desmopressin acetate) Oral Solution for Central Diabetes Insipidus

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating

ViiV Healthcare Reports Positive 12-Month Data Showing Investigational bNAb Lotivibart (N6LS) Maintains High Levels of Viral Suppression in Long-Acting HIV Treatment Regimen

London, 25 February 2026 ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced pos

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Gilead Sciences, Inc. (Nasdaq GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch